Lin Hong-Yuan
Forth Medical Center, General Hospital of PLA, Beijing, China.
Chin J Traumatol. 2020 Aug;23(4):190-195. doi: 10.1016/j.cjtee.2020.06.002. Epub 2020 Jun 15.
COVID-19 is known for its magical infectivity, fast transmission and high death toll based on the large number of infected people. From the perspective of the clinical manifestation, autopsy examination and pathophysiology, the essence of COVID-19 should be viewed as a sepsis induced by viral infection, and has the essential characteristics as sepsis induced by other pathogens. Therefore, in addition to etiological and supportive treatment, immunomodulatory therapy is also appropriate to severe COVID-19. Although there is still a lack of consensus on immunotherapy for sepsis so far, relatively rich experiences have been accumulated in the past decades, which will help us in the treatment of severe COVID-19. This article will elaborate immunotherapy of sepsis, though it may not be consistent.
新冠病毒肺炎（COVID-19）以其惊人的传染性、快速传播以及基于大量感染人群的高死亡率而闻名。从临床表现、尸检检查及病理生理学角度来看，COVID-19的本质应被视为一种由病毒感染诱发的脓毒症，具备其他病原体诱发脓毒症的基本特征。因此，对于重症COVID-19，除病原学及支持治疗外，免疫调节治疗同样适用。尽管目前对于脓毒症的免疫治疗仍缺乏共识，但在过去几十年里已积累了较为丰富的经验，这将有助于我们治疗重症COVID-19。本文将阐述脓毒症的免疫治疗，尽管可能并不全面。
